Melanoma

Melanoma treatment was transformed by BRAF/MEK targeted therapies and immune checkpoint inhibitors. Dual PD-1/LAG-3 blockade (nivolumab + relatlimab) and TIL cell therapy (lifileucel) represent the newest FDA approvals. mRNA neoantigen vaccines are under active investigation.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Melanoma

• Pembrolizumab (Keytruda) — Checkpoint Inhibitor
• Nivolumab (Opdivo) — Checkpoint Inhibitor
• Ipilimumab (Yervoy) — Checkpoint Inhibitor
• Relatlimab (Opdualag (with nivolumab)) — Checkpoint Inhibitor
• Vemurafenib (Zelboraf) — Tyrosine Kinase Inhibitor
• Dabrafenib (Tafinlar) — Tyrosine Kinase Inhibitor
• Trametinib (Mekinist) — Tyrosine Kinase Inhibitor
• Cobimetinib (Cotellic) — Tyrosine Kinase Inhibitor
• Binimetinib (Mektovi) — Tyrosine Kinase Inhibitor
• Encorafenib (Braftovi) — Tyrosine Kinase Inhibitor
• Lifileucel (Amtagvi) — Other